Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence
NCT03897062 · The Florey Institute of Neuroscience and Mental Health · PHASE2 · terminated · last registry update 2023-02-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Recruitment problems during covid lockdowns resulted in Merck ceasing supply of suvorexant/placebo” | – | Registry record, The Florey Institute of Neuroscience and Mental Health |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HCRTR2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-02-12Results posted on the registry: Milton S. Hershey Medical Center, Suvorexant 20 mg (NCT03412591)
- 2024-01-16Results posted on the registry: Massachusetts General Hospital, Suvorexant (NCT04706091)
- 2023-11-08Also stopped (withdrawn): Brendan Lucey, Lemborexant 25 mg + Placebo (NCT05728736)
- 2023-10-10Results posted on the registry: Eisai Inc., Placebo + Lemborexant 10 mg (NCT04647383)
- 2023-08-24Phase 3 first posted: Jiangsu Simcere Pharmaceutical Co., Ltd., Daridorexant + Placebo (NCT06010693)
- 2023-06-02Results posted on the registry: Howard University, suvorexant (NCT02849548)
- 2023-04-26Results posted on the registry: The Scripps Research Institute, Suvorexant 20 mg + Placebo oral tablet (NCT04229095)
- 2023-03-02Results posted on the registry: Massachusetts General Hospital, Suvorexant (NCT03818581)
- 2023-02-15Results posted on the registry: Howard University, suvorexant (NCT02704754)
- 2023-02-08Results posted on the registry: William Stoops, Suvorexant + Cocaine (NCT03937986)
- 2022-10-06Results posted on the registry: Stanford University, Suvorexant + Placebo (NCT02527564)
- 2022-08-16Results posted on the registry: Janssen Research & Development, LLC, JNJ-42847922 + Placebo Matching to JNJ-42847922 (NCT03321526)
- 2022-08-08Results posted on the registry: Johns Hopkins University, Placebo oral capsule + Low Dose Suvorexant (NCT03789214)
- 2022-07-14Phase 3 first posted: Baylor College of Medicine, Lemborexant 10 mg + Naltrexone (NCT05458609)
- 2022-05-23Results posted on the registry: Janssen Research & Development, LLC, Placebo + JNJ-42847922, 5 mg (NCT03375203)
- 2022-05-17Results posted on the registry: Washington University School of Medicine, Suvorexant + Placebo (NCT03077620)
- 2022-03-25Results posted on the registry: Idorsia Pharmaceuticals Ltd., Daridorexant (NCT03575104)
- 2022-03-25Results posted on the registry: Idorsia Pharmaceuticals Ltd., Daridorexant 25 mg + Daridorexant 50 mg (NCT03545191)
- 2022-03-02Results posted on the registry: Idorsia Pharmaceuticals Ltd., Daridorexant 10 mg + Daridorexant 25 mg (NCT03679884)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision